At BOME Therapeutics, we are driven by a mission to revolutionize Allergen Immunotherapy. Behind our groundbreaking advancements is a team with decades of collective experience in the life science industry, allergy and immunotherapy, pharmaceutical development, and medical research.
Together, we strive to redefine what’s possible and improve lives around the globe.
1122 N. High Street,
Millville, NJ 08332-2529
BOME’s immunotherapy is currently not FDA approved. We are in the process of further product refinement and hope to conduct clinical trials in the near future.
Henry Kim is a MedTech executive and consultant with over 20 years of experience in medical devices, SaaS, and healthcare solutions. As Principal Owner of KNEXT Consulting, he advises private equity, venture capital, startups, and established companies on strategy, commercialization, and product development. He has led teams and growth initiatives at Dimension Inx, STERIS, StrataMed Solutions, and Quality Means Business, with a proven track record in scaling innovation, securing funding, and delivering transformative healthcare solutions.
Robert is a board-certified allergist and innovator in immunology with a background in engineering physics. Guided by an engineer’s mindset—improving systems to make them better and more efficient—he transitioned from engineering to medicine to bring that approach to patient care. Over the course of his career, he has applied this philosophy to helping individual patients and small groups, and through the development of ADBP, his work now has the potential to bring relief to tens of millions.
Catherine Yang, Ph.D., will perform urushiol assays on samples sent to her in California. She is a chemist, the co-inventor of the PI/PO ADBP antigen, and the developer of a low-cost, FDA-compliant urushiol assay technology.
Millan Bhatt is the Chief Production Officer specializing in aseptic packaging and serves as Managing Partner of the Molecular Pharma Group, overseeing outside contracting.
Eric Feerst is a project manager with expertise in quality control, regulatory compliance, and project management.
Jonathan A. Bernstein, M.D., is a Professor at the University of Cincinnati and a past President of the American Academy of Allergy, Asthma, and Immunology. He is the advisor of BOME Therapeutics.